Towa Pharmaceutical Co., Ltd.
【Towa Pharmaceutical】Executive Change Notice | General Shareholders’ Meeting Scheduled for June 24, 2026
Towa Pharmaceutical announced that the official appointment of executive personnel will be decided at the general shareholders' meeting scheduled for June 24, 2026, and has announced the tentative candidates for new and reappointed directors.
Key Figures
- Number of director candidates: 8 (including new and reappointed)
- Tentative appointment date: May 21, 2026
- Scheduled formal decision date: June 24, 2026
AI要約
Overview of Executive Personnel Changes
Towa Pharmaceutical, at today’s board of directors meeting, announced a tentative decision regarding executive personnel changes. The candidates include President and CEO Isao Yoshida, among several others. These candidates are scheduled to be officially appointed at the 70th Annual General Meeting of Shareholders to be held on June 24, 2026. The new appointment includes Akikazu Sakae, who will serve as President and Chief Operating Officer and in charge of the Management Strategy Division, while other directors will be reappointed.
Impact of Executive Personnel Changes and Future Outlook
This executive personnel change aims to strengthen the company’s management structure and promote mid- to long-term business strategies. In particular, the role of Akikazu Sakae as President and COO is expected to play a key role in advancing management strategies. After the formal decision, it is expected that there will be a proactive rotation of directors to enhance corporate governance and support future business development.
Towa Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
